Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you.
Small molecule biomarkers provide the next layer of biological insight to help complete the picture of human health and disease that genetics and proteomics have formed to date.
Sapient’s Dr. Tanya Nguyen, Head of Scientific Operations, shares context of use examples for these biomarkers and the applications in which sponsors are seeing the greatest value and impact on their pipelines.
Because small molecule biomarkers are highly conserved across species, they are typically highly translatable, increasing the likelihood of finding a biomarker in early discovery research that can be applied in later clinical trials. This is an important feature of biomarkers for biopharma to advance drug development efforts and make findings actionable for clinical implementation.
Want to hear more from our Experts On additional discovery topics? Click here to see more videos.

Experts On… Delivering Value to Biopharma Sponsors
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. Small molecule biomarkers provide the next layer of biological insight to help complete the picture of human health and disease that genetics and… Read More

Experts On… The Impact of Chemical Discovery at Scale
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. Advancing precision medicine requires better understanding not only of how one patient differs from another, but also the factors that cause diseases and… Read More

Experts On… Making Biomarker Discoveries Actionable
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. Actionable insight. That is what’s needed to move from nontargeted discovery screenings to development of targeted clinical assays that can provide new diagnostics… Read More

Experts On… Multi-Omics Data Integration
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. To achieve the statistical power for robust discovery of biological insight, we often need to integrate multiple omics datasets – including high dimensional… Read More

Experts On… Machine Learning in Biomarker Discovery
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. How can machine learning (ML) be used to boost biomarker discovery potential? Sapient’s Co-Founder and Head of Chemical Discovery, Dr. Saumya Tiwari, shares… Read More

Experts On… Approaching Experimental Design
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. What does an engagement with Sapient look like? Hear from Dr. Tanya Nguyen, Sapient’s Head of Operations, as she explains how her team… Read More

Experts On… Defining Biocomputational Approaches
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those insights with you. In this segment, Sapient’s Co-Founder and Head of Data Science, Dr. Tao Long, shares how our data science team goes about determining the… Read More

“Live from the Lab” at Sapient: On-Demand Virtual Lab Tour with Bruker
Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high throughput rapid liquid chromatography-mass spectrometry (rLC-MS) platform leverages the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 to enable large-scale biomarker profiling. See… Read More

Advances in Proteomics & Metabolomics 2022 Online Symposium
Now On Demand | Presented by Technology Networks WATCH NOW Technology Networks invited Sapient’s Founder and CEO, Dr. Mo Jain, to this symposium to give a talk on: Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small… Read More

Genomic + Small Molecule Biomarkers: for a More Complete Picture of Disease Risk
An individual’s phenotype is not dictated solely by their genetic variants. Environmental factors – where we live, what we eat, exposures over time – interact with genes and can influence disease risk. See how small molecule biomarkers can be used to assess these environmental exposures and their influence on… Read More